Altimmune reported a net loss of $22.8 million for Q3 2024, compared to $20.7 million in Q3 2023, with total revenue declining to $5,000 from $362,000. Research and development expenses increased 8% to $19.8 million, primarily driven by the advancement of pemvidutide clinical trials. The company ended the quarter with $139.4 million in cash and investments.The company achieved significant progress with pemvidutide, completing enrollment in the Phase 2b IMPACT trial for MASH treatment, with top-line data expected in Q2 2025. Additionally, Altimmune successfully concluded its End-of-Phase 2 Meeting with the FDA, reaching agreement on the design of Phase 3 registrational program for obesity treatment, which will include four trials enrolling approximately 5,000 subjects.Management maintains that current cash reserves are sufficient to fund operations for at least 12 months. The company continues to focus on developing treatments for obesity and liver diseases, with pemvidutide showing promising results in body composition analysis, including 78.1% of weight loss derived from adipose tissue and only 21.9% from lean mass in the MOMENTUM Phase 2 obesity trial.

Altimmune reported a net loss of $22.8 million for Q3 2024, compared to $20.7 million in Q3 2023, with total revenue declining to $5,000 from $362,000. Research and development expenses increased 8% to $19.8 million, primarily driven by the advancement of pemvidutide clinical trials. The company ended the quarter with $139.4 million in cash and investments.The company achieved significant progress with pemvidutide, completing enrollment in the Phase 2b IMPACT trial for MASH treatment, with top-line data expected in Q2 2025. Additionally, Altimmune successfully concluded its End-of-Phase 2 Meeting with the FDA, reaching agreement on the design of Phase 3 registrational program for obesity treatment, which will include four trials enrolling approximately 5,000 subjects.Management maintains that current cash reserves are sufficient to fund operations for at least 12 months. The company continues to focus on developing treatments for obesity and liver diseases, with pemvidutide showing promising results in body composition analysis, including 78.1% of weight loss derived from adipose tissue and only 21.9% from lean mass in the MOMENTUM Phase 2 obesity trial.